| [1]Najeeb S, Siddiqui F, Khurshid Z, et al.Effect of bisphosphonates on root resorption after tooth replantationa systematic review[J].Dent Traumatol, 2017, 33(2):77-83[2]郭玉兴, 王佃灿, 安金刚, 等.二膦酸盐颌骨骨髓炎例临床特点分析[J].中华口腔医学杂志, 2014, 49(9):517-520[3]Woo SB, Solomon DH.Bisphosphonate therapy for cancer and prevalence of inflammatory jaw conditions[J].J Natl Cancer Inst, 2007, 99(13):986-987[4]Trivedi S, AlNofal A, Kumar S, et al.Severe noninfective systemic inflammatory response syndrome,shock,and endorgan dysfunction after zoledronic acid administration in a child[J].Osteoporos Int, 2016, 27(7):2379-2382[5]Harvey EJ.Bisphosphonates are not always helpful: Commentary on an article by HaeSeong Lim,MD,et al : “Factors associated with increased healing time in complete femoral fractures after longTerm bisphosphonate therapy”[J].J Bone Joint Surg Am, 2016, 98(23):e107-[6]CuevasGonzález MV, DíazAguirre CM, EchevarríaYPérez E, et al.Prevalence of osteonecrosis of the jaw and oral characteristics of oncologic patients treated with bisphosphonates at the General Hospital of Mexico[J].J Korean Assoc Oral Maxillofac Surg, 2016, 42(6):365-369[7]李彦博, 刘霏霏.双膦酸盐和下颌骨坏死[J].现代肿瘤医学, 2012, 20(5):1065-1068[8]Goodwin JS, Zhou J, Kuo YF, et al.Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer[J].Mayo Clin Proc, 2017, 92(1):106-113[9]Schwartz HC.American association of Oral and Maxillofacial Surgeons position paper on medicationrelated osteonecrosis of the jaw—2014 update and CTX[J].J Oral Maxillofac Surg, 2015, 73(3):377-[10]Junquera L, Gallego L.Nonexposed bisphosphonaterelated osteonecrosis of the jaws: another clinical variant?[J].J Oral Maxillofac Surg, 2008, 66(7):1516-1517[11]Fedele S, Porter SR, D' Aiuto F, et al.Nonexposed variant of bisphosphonateassociated osteonecrosis of the jaw: a case series[J].Am J Med, 2010, 123(11):1060-1064[12]Bedogni A, Saia G, Ragazzo M, et al.Bisphosphonateassociated osteonecrosis can hide jaw metastases[J].Bone, 2007, 41(6):942-945[13]Weinstein RS, Roberson PK, Manolagas SC.Giant osteoclast formation and longterm oral bisphosphonate therapy[J].N Engl J Med, 2009, 360(1):53-62[14]Cartsos VM, Zhu S, Zavras AI.Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people[J].J Am Dent Assoc, 2008, 139(1):23-30[15]Koth VS, Figueiredo MA, Salum FG, et al.Bisphosphonaterelated osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a nonexposed BRONJ entity[J].Dentomaxillofac Radiol, 2016, 45(7):20160049-[16]Mücke T, Krestan CR, Mitchell DA, et al.Bisphosphonate and medicationrelated osteonecrosis of the jaw: A review[J].Semin Musculoskelet Radiol, 2016, 20(3):305-314[17]Yarom N, Goss A, Lazarovici TS, et al.Bisphosphonaterelated osteonecrosis of the jaw[J].J Am Dent Assoc, 2016, 147(10):776-777[18]Guo YX, Misra G, Guo CB, et al.Reeconstruction of a mandibular defect after bisphosphonaterelated osteonecrosis of the jaw[J].Br J Oral Maxillofac Surg, 2016, 54(8):962-964[19]de Castro MS, Ribeiro NV, de Carli ML, et al .Photodynamically dealing with bisphosphonaterelated osteonecrosis of the jaw: Successful case reports［J］. Photodiagnosis Photodyn Ther, 2016, 16:72-75.[20]Sun Y, Kaur K, Kanayama K, et al.Plasticity of myeloid cells during oral barrier wound healing and the development of bisphosphonaterelated osteonecrosis of the jaw[J].J Biol Chem, 2016, 291(39):20602-20616[21]Sánchez A, Blanco R.Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates[J].Osteoporos Int, 2017, 28(3):1145-1147[22]Faiman B, Pillai AL, Benghiac AG.Bisphosphonaterelated osteonecrosis of the jaw: historical,ethical,and legal issues associated with prescribing[J].J Adv Pract Oncol, 2013, 4(1):25-35[23]黄如冰, 吴晓林, 俞娟.双磷酸盐相关性颌骨坏死例临床分析[J].中华口腔医学研究杂志电子版, 2012, 6(4):353-357[24]Kim HJ, Park TJ, Ahn KM.Bisphosphonaterelated osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases[J].Maxillofac Plast Reconstr Surg, 2016, 38(1):6-[25]Rahim I, Salt S, Heliotis M.Successful longterm mandibular reconstruction and rehabilitation using nonvascularised autologous bone graft and recombinant human BMP7 with subsequent endosseous implant in a patient with bisphosphonaterelated osteonecrosis of the jaw[J].Br J Oral Maxillofac Surg, 2015, 53(9):870-874[26]Lesclous P, Abi NS, Carrel JP, et al.Bisphosphonateassociated osteonecrosis of the jaw: a key role of inflammation?[J].Bone, 2009, 45(5):843-852[27]华洪飞, 王宁涛, 张文杰, 等.双膦酸盐致颌骨坏死的大鼠模型研究[J].口腔颌面外科杂志, 2016, 26(1):19-24[28]Khosla S, Burr D, Cauley J, et al.Bisphosphonateassociated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research[J].J Bone Miner Res, 2007, 22(10):1479-1491[29]Stresing V, Fournier PG, Bellahcène A, et al.Nitrogencontaining bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase[J].Bone, 2011, 48(2):259-266[30]Soki FN, Li X, Berry J, et al.The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches[J].J Cell Biochem, 2013, 114(1):67-78[31]Nakamura K, Fukumoto T, Fukui T, et al.A case of bisphosphonaterelated osteonecrosis of the jaw with difficulty in treatment[J].Hinyokika Kiyo, 2016, 62(1):39-44[32]Sun J, Wen X, Jin F, et al .Bioinformatics analyses of differentially expressed genes associated with bisphosphonaterelated osteonecrosis of the jaw in patients with multiple myeloma［J］. Onco Targets Ther, 2015, 8:2681-2688.[33]Dudek NL, Croft NP, Schittenhelm RB, et al .A systems approach to understand antigen presentation and the immune response［J］. Methods Mol Biol, 2016, 1394:189-209.[34]Kennedy RB, Ovsyannikova IG, Haralambieva IH, et al .Immunosenescencerelated transcriptomic and immunologic changes in older individuals following influenza vaccination［J］. Front Immunol, 2016, 7:450.[35]Bignami F, Pilotti E, Bertoncelli L, et al.Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV1[J].Blood, 2012, 119(26):6259-6267[36]Kalyan S, Wang J, Quabius ES, et al .Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonateassociated osteonecrosis of the jaw［J］. J Transl Med, 2015, 13:212.[37]Nisi M, La Ferla F, Karapetsa D, et al.Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis[J].Int J Oral Maxillofac Surg, 2015, 44(5):586-591[38]Chiu WY, Chien JY, Yang WS, et al.The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene[J].J Clin Endocrinol Metab, 2014, 99(8):2729-35[39]Wessel JH, Dodson TB, Zavras AI.Zoledronate,smoking,and obesity are strong risk factors for osteonecrosis of the jaw: a casecontrol study[J].J Oral Maxillofac Surg, 2008, 66(4):625-31[40]Huang YF, Chang CT, Muo CH, et al.Impact of bisphosphonaterelated osteonecrosis of the jaw on osteoporotic patients after dental extraction: a populationbased cohort study[J].PLoS One, 2015, 10(4):e0120756-[41]Khosla S, Burr D, Cauley J, et al.Oral bisphosphonateinduced osteonecrosis: risk factors,prediction of risk using serum CTX testing,prevention,and treatment[J].J Oral Maxillofac Surg, 2008, 66(6):1320-1321[42]Marx RE, Cillo JE, Ulloa JJ.Oral bisphosphonateinduced osteonecrosis: risk factors,prediction of risk using serum CTX testing,prevention,and treatment[J].J Oral Maxillofac Surg, 2007, 65(12):2397-410[43]JP2〗Hutcheson A, Cheng A, Kunchar R, et al.A Cterminal crosslinking telopeptide testbased protocol for patients on oral bisphosphonates requiring extraction: a prospective singlecenter controlled study[J].J Oral Maxillofac Surg, 2014, 72(8):1456-62[44]Lee CY, Suzuki JB.CTX biochemical marker of bone metabolismIs it a reliable predictor of bisphosphonateassociated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature[J].Implant Dent, 2009, 18(6):492-500[45]Lee CY, Suzuki JB.CTX biochemical marker of bone metabolismIs it a reliable predictor of bisphosphonateassociated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study[J].Implant Dent, 2010, 19(1):29-38 |
